FO
ALXN

FT Options’s Alexion Pharmaceuticals ALXN Stock Holding History

FT Options’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$914K Buy
+6,518
New +$886K 1.38% 25
2017
Q1 		– Sell
-16,335
Closed -$2M – 381
2016
Q4 		$2M Buy
+16,335
New +$2M 2.3% 10
2016
Q3 		– Sell
-8,673
Closed -$1.01M – 466
2016
Q2 		$1.01M Buy
8,673
+5,100
+143% +$724K 0.87% 26
2016
Q1 		$497K Sell
3,573
-2,114
-37% -$310K 0.52% 41
2015
Q4 		$1.08M Buy
+5,687
New +$993K 0.8% 36

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FT Options's ALXN Position: Q3 2017 in Review

FT Options opened a new position in Alexion Pharmaceuticals (ALXN) in Q3 2017: 6,518 shares worth $914K. The stake represents 1.38% of the portfolio and ranks #25 among its holdings. This is a return to the name: FT Options previously reported a position in ALXN as recently as Q4 2016.

FT Options first reported a position in ALXN in Q4 2015 and has held it in 5 quarters since. The position peaked at $2M in Q4 2016. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • FT Options held 6,518 shares of Alexion Pharmaceuticals worth $914K as of Q3 2017.
  • Alexion Pharmaceuticals was a new FT Options position in Q3 2017.
  • Alexion Pharmaceuticals made up 1.38% of FT Options's portfolio in Q3 2017, its #25 holding.
  • FT Options first reported a position in Alexion Pharmaceuticals in Q4 2015 and has held it in 5 quarters since.
  • FT Options's Alexion Pharmaceuticals position peaked at $2M in Q4 2016.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.